Is entecavir (ETV) effective for the treatment of HBeAg-negative hepatitis B (HBV) (Hep B)?

Updated: Jun 08, 2021
  • Author: Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF; Chief Editor: BS Anand, MD  more...
  • Print

In an HBeAg-negative population, administration of 0.5 mg of entecavir in patients who were naïve to nucleoside analogues compared with patients who received 100 mg of 3TC for a duration of 48 weeks resulted in histologic improvement in 71% of the entecavir group, versus 61% of the 3TC group. [75] Undetectable serum HBV DNA levels were found in 90% of the entecavir-treated patients, versus 72% of the 3TC-treated patients.

Normalized ALT levels were achieved in 78% of the entecavir group, compared with 71% of the 3TC group. [75] The mean reduction in serum HBV DNA levels from baseline to week 48 was 5.0 log copies/mL (on a base-10 scale) in the entecavir-treated patients, versus 4.5 log copies/mL in the 3TC-treated patients. [75]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!